TY - JOUR
T1 - Polymorphic variability in the interleukin (IL)-1β promoter conditions susceptibility to severe malarial anemia and functional changes in IL-1β production
AU - Ouma, Collins
AU - Davenport, Gregory C.
AU - Awandare, Gordon A.
AU - Keller, Christopher C.
AU - Were, Tom
AU - Otieno, Michael F.
AU - Vulule, John M.
AU - Martinson, Jeremy
AU - Ong'echa, John M.
AU - Ferrell, Robert E.
AU - Perkins, Douglas J.
PY - 2008/10/15
Y1 - 2008/10/15
N2 - Interleukin (IL)-1β is a cytokine released as part of the innate immune response to Plasmodium falciparum. Because the role played by IL-1β polymorphic variability in conditioning the immunopathogenesis of severe malarial anemia (SMA) remains undefined, relationships between IL-1β promoter variants (-31C/T and -511A/G), SMA (hemoglobin [Hb] level <6.0 g/dL), and circulating IL-1β levels were investigated in children with parasitemia (n = 566) from western Kenya. The IL-1β promoter haplotype -31C/-511A (CA) was associated with increased risk of SMA (Hb level <6.0 g/dL; odds ratio [OR], 1.98 [95% confidence interval {CI}, 1.55-2.27]; P < .05) and reduced circulating IL-1β levels (P < .05). The TA (-31T/-511A) haplotype was nonsignificantly associated with protection against SMA (OR, 0.52 [95% CI, 0.18 -1.16]; P = .11) and elevated IL-1β production (P < .05). Compared with the non-SMA group, children with SMA had significantly lower IL-1β levels and nonsignificant elevations in both IL-1 receptor antagonist (IL-1Ra) and the ratio of IL-1Ra to IL-1β. The results presented demonstrate that variation in IL-1β promoter conditions susceptibility to SMA and functional changes in circulating IL-1β levels.
AB - Interleukin (IL)-1β is a cytokine released as part of the innate immune response to Plasmodium falciparum. Because the role played by IL-1β polymorphic variability in conditioning the immunopathogenesis of severe malarial anemia (SMA) remains undefined, relationships between IL-1β promoter variants (-31C/T and -511A/G), SMA (hemoglobin [Hb] level <6.0 g/dL), and circulating IL-1β levels were investigated in children with parasitemia (n = 566) from western Kenya. The IL-1β promoter haplotype -31C/-511A (CA) was associated with increased risk of SMA (Hb level <6.0 g/dL; odds ratio [OR], 1.98 [95% confidence interval {CI}, 1.55-2.27]; P < .05) and reduced circulating IL-1β levels (P < .05). The TA (-31T/-511A) haplotype was nonsignificantly associated with protection against SMA (OR, 0.52 [95% CI, 0.18 -1.16]; P = .11) and elevated IL-1β production (P < .05). Compared with the non-SMA group, children with SMA had significantly lower IL-1β levels and nonsignificant elevations in both IL-1 receptor antagonist (IL-1Ra) and the ratio of IL-1Ra to IL-1β. The results presented demonstrate that variation in IL-1β promoter conditions susceptibility to SMA and functional changes in circulating IL-1β levels.
UR - http://www.scopus.com/inward/record.url?scp=54749089534&partnerID=8YFLogxK
U2 - 10.1086/592055
DO - 10.1086/592055
M3 - Article
C2 - 18781863
AN - SCOPUS:54749089534
SN - 0022-1899
VL - 198
SP - 1219
EP - 1226
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 8
ER -